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“Alle Dinge sind Gift, und nichts ist ohne Gift; allein die  
dosis machts, das sein Ding kein Gift sei” 
[Paracelsus, 1493 – 1541] 
 
“Problems worthy of attack prove their worth by fighting back.” 
[Piet Hein, 1905 – 1996]  
In vitro toxicity testing using human 
pluripotent stem cell derivatives 
Gustav Holmgren 
ABSTRACT 
Toxicity testing of chemicals, drug candidates, and food additives is in need of a 
change. The present methods, mainly consisting of animal models with their 
associated ethical concerns, are expensive, time-consuming, and importantly they 
are often poor predictors of the human in vivo toxicity. With the rapid 
biotechnology development, a paradigm shift for toxicity testing is emerging, 
focusing on bioinformatics, computational toxicity, systems biology, and cell-
based in vitro models. 
The aim of this thesis was to investigate the utility of using cells, i.e. hepatocytes 
and cardiomyocytes, derived from human pluripotent stem cells (hPSC) as in vitro 
models for toxicity testing. The first part explored the feasibility of using hPSC-
derived hepatocytes to study toxic drug exposure, and in addition investigated the 
relevancy of the cellular response. The second and major part of this thesis 
focused on hPSC-derived cardiomyocytes and the in-depth study of doxorubicin-
induced toxicity.  
The studies revealed that the differentiation processes and culturing of hPSC-
derivatives are stable and reproducible to form the basis for in vitro models for 
toxicity testing, even for longer studies over two weeks. The hepatocytes and the 
cardiomyocytes showed sensitivity towards the toxic compounds and both cell 
models displayed a relevant cellular response to the toxic exposure. For example, 
the hepatocytes showed evidence of steatosis and phospholipidosis when 
incubated with hepatotoxic compounds over time. Besides an evident effect of 
doxorubicin on the cardiomyocyte function, the cells also proved to be useful for 
more in-depth mechanistic evaluations, as these studies gave insight, on multiple 
biological levels, in plausible mechanisms and identified potential biomarkers for 
doxorubicin-induced cardiotoxicity. 
In conclusion, this thesis presents findings that supports the vision and strategy 
of using in vitro models based on hPSC-derivatives together with advanced omics 
technologies for toxicity testing and risk assessment of drugs, food additives, and 
chemicals.   
 Keywords: toxicity testing, human pluripotent stem cells, cardiomyocytes, 
hepatocytes, microarray, quantitative proteomics, bioinformatics, 
transcriptomics, microRNA 
  
SAMMANFATTNING PÅ SVENSKA 
Riskbedömning och toxicitetstestning av läkemedel, kemikalier, och ingredienser 
i mat och kosmetika står inför ett regimskifte när det gäller vilka metoder man 
använder. De traditionella metoderna för att testa toxicitet (ämnens giftighet) 
innefattar framför allt försöksdjur och utvärdering av systemiska effekter och 
patologiska förändringar i dessa försöksdjur. Detta innebär ofta kostsamma, 
tidskrävande försök, lidande för djuren i fråga, och en låg korrelation till humana 
in vivo situationen, det vill säga det verkliga förhållandet i människokroppen. Med 
resultat från de senast årens utveckling inom cellbiologi och bioteknologi har en 
vision om en ny strategi för toxicitetstestning skapats. Denna strategi grundar sig 
i att man vill bygga en robust kunskapsplattform för bedömning av ämnens 
toxiska påverkan, baserat på mekanistiska studier av de processer som ett visst 
ämne påverkar i mänskliga celler, vävnader och individer. 
Syftet med denna avhandling var att utvärdera användningen av cell-baserade 
modeller, så kallade in vitro modeller, från human pluripotenta stamceller (hPSC) 
för att studera ämnens toxicitet. Stamceller är celler med obegränsad förmåga att 
föröka sig och med en potential att mogna ut till flera eller alla celltyper den 
mänskliga kroppen är uppbyggd av. Dessa celler utgör därför en optimal källa för 
cell-baserade modellsystem.  
Avhandlingens första delprojekt syftar till att utvärdera hur hPSC-deriverade 
hepatocyter (leverceller) svarar vid exponering för kända levertoxiska substanser. 
Det andra delprojektet syftar till att utvärdera användningen av hPSC-deriverade 
kardiomyocyter (hjärtmuskelceller) för att i detalj studera toxicitet orsakad av 
läkemedlet doxorubicin vars biverkningar inkluderar hjärttoxicitet.  
I dessa forskningsprojekt har vi kunnat visa på att celltyperna från hPSC kan 
genereras och odlas på ett robust och reproducerbart vis, vilket möjliggör 
toxicitetsstudier, även under så lång tid som två veckor. Hepatocyterna svarar på 
ett relevant sätt och man ser en ökad känslighet hos cellerna om de utsätts för 
toxiska substanser under längre tid. På liknande sätt svarar kardiomyocyterna på 
ett relevant sätt vid exponering för doxorubicin. En tydlig påverkan ses på cellerna 
i form av försämrad funktion och förändrat utseende. Förutom detta visar 
studierna även på att man, med hjälp av avancerade tekniker som mäter cellers 
totala gen- och proteinuttryck (microarray och kvantitativ proteomik), kan studera 
ingående mekanistiska effekter av doxorubicin i cellerna. Resultaten visar på 
påverkade processer både på gennivå och proteinnivå och flertalet potentiella 
 biomarkörer, det vill säga gener eller proteiner som möjligen kan användas för att 
förutspå toxiciteten, har identifierats. 
Sammanfattningsvis visar den här avhandlingen på att cellmodeller baserade på 
hPSC kan användas för toxicitetstestning. Avhandlingen styrker visionen om att 
använda cellbaserade modellsystem för att i framtiden bättre kunna förutse 
ämnens toxicitet och riskbedöma substanser och därmed minska eller eventuellt 
helt utesluta djurförsök. 
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1 INTRODUCTION 
1.1 General Toxicology 
The study of poison and poisonous effects to living organisms has an ancient 
history. From the animal and plant toxins used by African Bushmen and South 
American Indian tribes to the Egyptian’s interest in plant toxins, such as opium, 
and mineral toxins, such as lead and copper, over 1000 years BC. The ancient 
Greeks moved the development further with observational and experimental 
studies of toxins and their antidotes. The term toxicology originates from the 
Greek word for poison: toxicon. Studies of poisons continued during the middle 
ages and the renaissance, not least with the recurrent use of poisons in the 
frequent events of homicides. Paracelsus (1493 – 1541), sometimes referred to as 
the ‘father’ of toxicology stated in the late 1530’s the famous phrase: ‘Alle Ding 
sind Gift und nichts ohn' Gift; allein die Dosis macht, das ein Ding kein Gift ist’ 
(‘All things are poison and nothing (is) without poison; only the dose makes that 
a thing is no poison’)1. The founder of modern toxicology is often considered to 
be Mathieu J B Orfila, who in 1813 published his ‘Traité de toxicologie’, which 
describes symptoms and adverse effects of poisons and chemicals. 
Toxicology is in modern time generally referred to as the study of adverse effects 
of chemicals in living organisms and is a segment within biology, chemistry, and 
medicine (or pharmacology). In the pharmaceutical industry, toxicology, to the 
far most, associates with the safety assessment of drug candidates often consisting 
of synthetic chemicals. The term does not only include the study of synthetic 
chemicals but also refers to studies of harmful effects by agents of biological or 
physical origin.  
Early safety assessment during drug development in general has been focused on 
animal models. However, there are numerous cases in the history that stress that 
non-human mammals are poor predictors of human toxicities. The disaster with 
Thalidomide (with the brand name Neurosedyn) in the late 1950’s and early 
1960’s, resulting in a huge number (>10000) of severe birth defects in children, is 
often referred to as the biggest man-made medical disaster in history2. The 
thalidomide case demonstrated for the first time that species differences exist in 
drug reactions/responses and the disaster completely changed the way drugs are 
tested. Nevertheless, despite comprehensive toxicity testing there are still today 
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many events of unexpected human toxicity of drugs leading to late attrition of 
drug candidates and already marketed drugs. 
The attrition rates of drug candidates are a major concern for the pharmaceutical 
industry, and in the late 1990s only approximately one out of nine candidates 
made it through development and were approved by regulatory authorities as the 
European Medicines Agency (EMA) and/or the US Food and Drug 
Administration (FDA). Besides efficacy, safety reasons were the major 
contributor to late-stage attrition rates during drug development3. A more recent 
study by Hay et al. reports that only approximately 10% of the candidates entering 
clinical phase I trials is expected to advance to FDA approval4. One explanation 
of the continuous increase in late-stage attrition rates is that the study by Hay et 
al. included small biotech companies, with the tendency of developing less 
validated drug classes and targets, and having less experience and fewer resources 
than large pharmaceutical corporations. This report suggests amongst other, more 
predictive test models, earlier toxicology evaluation, and biomarker identification 
as potential improvements to increase the success rate in the future4. 
Due to the poor prediction of human toxicities by non-human mammals, one 
cannot expect that in vitro systems based on cells derived from such animals would 
do any better. The way to move forward in that sense therefore lays in the 
development of in vitro systems based on human cells.  
Over 40 years ago, Russel and Burch elaborated the term of the Three R’s 
(replace, reduce, refine) in the context of live animal experiment. Since then, much 
have been done in the field of replacement, reduction, and refinement of animal 
studies, but there is still a lot of work to be done5. In 2007, the U.S. National 
Academy of Science presented a new strategy, illustrated in figure 1, for toxicity 
testing in their report “Toxicity Testing in the 21st Century: A Vision and a 
Strategy”6. The vision for the strategy is an increased efficiency in toxicity testing 
and a reduced animal use, by a transition from animal in vivo testing to in vitro 
toxicity pathway assays with human cells or cell lines using high-throughput 
screening with mechanistic quantitative parameters. Risk assessment with this 
strategy would focus on avoiding significant disturbance in the key identified 
toxicity pathways7. As an example, the Swedish national academic research center 
Swetox implements this new vision of safety assessment as the three M’s 
(mechanisms, markers, models), where the focus is to use in vitro, in silico, and 
chemical analysis, to retrieve knowledge of the toxic mechanisms and identify 
specific biomarkers to develop new models for safety assessment. 
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Biomarkers can be defined as a quantifiable object that allows for the detection 
of a biological event, representing either normal physiology or a pathological state. 
A biomarker would ideally provide mechanistic information and be translatable 
to the clinic.  
 
Figure 1. New vision of toxicity testing. Illustration of the vision of a new strategy for toxicity 
testing and the potential contribution of hPSC-derivatives.  
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1.2 Hepatotoxicity 
The term hepatotoxicity refers to the damage of the liver often induced by a 
chemical agent. The liver is one of the most, if not the most, important target 
organ for drug-induced toxicity. This vulnerability is mainly associated with the 
function of the liver and its role in detoxification of various metabolites, including 
most drugs. The compounds generating the most interest from the 
pharmaceutical industry are the ones causing drug-induced liver injury (DILI). 
The list of compounds that are considered potentially toxic to the liver is extensive 
and DILI has been associated with over one-third of the acute liver failure cases 
in the USA8, 9. Negative effects on the hepatic function is the leading cause of 
drug failure in clinical trials and retraction of post-market drugs10.  
Preclinical animal models have a weak potential of predicting human DILI, mainly 
due to large species differences in drug metabolism and toxicity targets11, 12. 
Therefore, during the last decades, large efforts have been made to replace 
laboratory animals with alternative human cell-based systems. The gold standard 
of today for hepatotoxicity studies are primary human hepatocytes (PHH). 
However, the shortage of appropriate human liver samples and the fact that, 
despite improved in vitro culturing systems, the cells rapidly lose key enzymes 
involved in metabolizing and transporter functions in culture13-15, hinders the 
widespread use of PHH. Furthermore, alternative human liver cell lines, especially 
human hepatoma cell lines, can in some aspects replace PHH but, on the other 
hand, they show inadequate expression of important metabolizing and 
transporting enzymes16, 17.  
HepG2 is one of the most frequently used hepatoma cell lines for hepatotoxic 
evaluations and is, because of its widespread use, also the best characterized. 
HepG2 cells, like other available hepatoma cell lines, offer some key advantages, 
such as unlimited life span, reproducibility, easy handling, and accessibility. Using 
HepG2 cells cultured in small scale formats (e.g., 96- or 386-well plates) together 
with automated imaging techniques and high content screening assays is 
considered a very valuable platform for hepatotoxic predication during preclinical 
development18-20. However, because of the very poor expression of key drug-
metabolizing enzymes in HepG2 cells, their use to detect metabolism-induced 
toxicity is limited21, 22. Using HepG2 cells for this type of studies can lead to 
inaccurate detection of cell toxicity as well as over-estimation of toxicity from 
normally highly-metabolized parent drugs17.  
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HepaRG cells are often considered the most promising alternative to PHH for in 
vitro studies. HepaRG are proliferating hepatic progenitor cells with the capacity 
of becoming both hepatocyte-like and biliary-like cells23. The great advantage of 
these cells are their liver-characteristics and especially the fact that they express 
higher phase I and phase II metabolizing enzymes than any other hepatoma cell 
line22. The ability to culture HepaRG cells for long time without loss of the 
metabolic features opens up for potential long term studies of chronic toxicity24. 
Due to these features, the usage of HepaRG cells for hepatotoxic assessment is 
growing. Several studies show supporting results for HepaRG as a tool for 
hepatotoxic assessment, however, the number of toxicity screening studies 
involving larger sets of compounds are few. 
A recent study on four hepatic in vitro cell models (including PHH, HepG2, 
Upcyte hepatocytes, and HepaRG) for the assessment of compounds causing 
DILI, reported that none of the tested cell models fully could distinguish between 
DILI and non-DILI compounds, using a simple read-out as the determination of 
effective concentration 50% (EC50) values25.  The report stresses the fact that 
current in vitro cell models need further development, both regarding cellular 
features as well as in the readouts or endpoints to measure. 
1.3 Cardiotoxicity 
 One event that has underscored the need to focus on safety assessment during 
clinical development is the incident in 2004 when Vioxx® (rofecoxib) was 
withdrawn from the market by FDA. Vioxx® is a nonsteroidal anti-inflammatory 
drug (selective Cyclooxygenase-2 inhibitor) that was found to be associated with 
an unforeseen increased risk of cardiovascular side effects. Besides the suffering 
of those individuals affected, the withdrawal resulted in a tremendous cost due to 
lost revenues and patient lawsuits and illustrate the need for better and more 
predictive pre-clinical models26.  
The heart is a complex organ consisting of many different cell types, where the 
most crucial function is to pump blood through the rest of the body. 
Dysregulation of the cardiovascular system is a major health concern and 
cardiovascular disease is the leading cause of death worldwide27.  
Cardiotoxicity is a term that describes the damage of cardiomyocytes resulting in 
decreased cardiac function. The reduced cardiac function can be caused by 
impaired electrical properties of the heart due to interactions with ion channels 
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or alterations in the potassium currents within the cardiomyocytes28, 29. Other 
compounds, often associated with anti-cancer treatment, can result in 
cardiotoxicity independent of the cardiomyocyte’s electrical activities. The 
mechanisms of toxicity for these compounds vary a lot and include for instance, 
mitochondrial dysfunction, DNA damage, reactive oxygen species formation, and 
apoptosis30.  
A variety of model systems are used to evaluate the efficacy and safety of 
thousands of compounds during the early phases of drug discovery. The current 
standard for preclinical drug testing is animal models, primarily rodent models. 
For cell-based assays, cell lines such as H9c2, derived from embryonic rat 
ventricle31, or the HL-1 cell line derived from the AT-1 mouse atrial CM tumor 
lineage32 have been used for many decades. With increased knowledge in genetic 
engineering and the human genome, cell lines (commonly from Chinese hamster 
ovary or human embryonic kidney) with artificially over-expressed ion channels 
(especially the human ether-a-go-go-related gene (hERG)) have been a preferred 
choice from the pharmaceutical industry33. However, these assays typically only 
provide information on drug effects on single ion channels, and for a more 
complex analysis isolated tissue or cardiomyocytes from animals are used. These 
models commonly originate from rabbit or dog, and the advantages are that the 
cardiomyocytes are mature and that tissue models constitute a multicellular 
system. The main concerns with these models are the species differences; no 
animal model can fully recapitulate the human cardiomyocyte33.  
During safety assessment of new candidate drugs, screening for drugs affecting 
the hERG plays a critical role. The hERG channel is an important potassium 
channel responsible for the repolarization of the cardiac action potential. A 
diverse set of drugs have been observed to increase the tendency of blockage of 
this potassium current, resulting in a prolonged action potential depolarization 
and an increased risk of a potentially lethal ventricular arrhythmia called Torsade 
de Pointes34, 35. A model system consisting of mammalian cells that express hERG 
channels has been, and still provides, a valuable tool for the evaluation of acute 
impact of new test compounds on this channel in high-throughput screening. 
However, a major concern with this method is the strong focus on one single ion 
channel, with the risk of false negatives and false positives due to the lack of other 
ion channels and cell surface receptors. During the decade of testing this model 
system, it has become clear that this is a conservative approach that might have 
resulted in the attrition of potentially useful drugs based solely on their effect on 
the hERG rather than an evident induction of arrhythmia36. 
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In the light of the acquired experience with hERG screening, in 2013, 
representatives from the Cardiac Safety Research Consortium (CSRC), Health 
and Environmental Sciences Institute (HESI), and the US FDA organized a work-
shop with the focus to reconsider approaches for the evaluation of drug-induced 
arrhythmia. The group ended up with a proposal of a new paradigm named 
Comprehensive In vitro Proarrhythmia Assay (CiPA), a new approach for the early 
evaluation of the proarrhythmic risk of compounds37, 38.  The CiPA-initiative 
consists of two series of tests: First, the in vitro study of drug effects on multiple 
ion channels as input data for an in silico model of the adult human ventricular 
myocyte to assess the proarrhythmic risk. Secondly, the use of human ventricular 
myocytes, likely derived from human induced pluripotent stem cells (hiPSC), to 
confirm the ion currents and the in silico results36. Training, calibration, and 
subsequent validation of the CiPA initiative is currently ongoing, and if successful, 
it will most likely have a major impact on the cardiac safety assessment in the 
pharmaceutical industry in the future. 
1.3.1 Anthracycline-induced cardiotoxicity 
As mentioned above, many chemotherapeutic agents are associated with 
cardiotoxic side effects, and chemotherapeutic-induced cardiomyopathy is one of 
the leading causes of disease and mortality in cancer survivors. Among the most 
cardiotoxic chemotherapeutic drugs present on the market today are 
anthracyclines, such as doxorubicin, which are highly efficient agents for a variety 
of cancers, including hematologic malignancies, soft tissue sarcomas, and solid 
tumors in both children and adults39-41.  
The anti-tumor effects of anthracyclines manifest primarily as inhibition of DNA 
replication and transcription, since the main cellular target of anthracyclines is 
believed to be topoisomerase II42. The role of anthracyclines as ‘topoisomerase 
poisons’ is due to the blockage of DNA resealing during replication and 
transcription. Anthracyclines stabilizes the intermediate where the DNA strands 
are cut and covalently bound to topoisomerase II43. This results in impaired DNA 
replication and transcription as well as the DNA strand break may trigger 
apoptosis in the cells. Anthracyclines thereby leads to the killing of rapidly 
dividing cells and in turn slows down tumor progression, features of the 
anthracyclines that has been known for more than 30 years. The wide-spread 
success of these compounds as chemotherapeutic agents is, however, hampered 
due to toxicity to non-cancerous cells, especially cardiomyocytes44, 45. Over the 
years a substantial number of anthracycline analogs have been synthesized and 
tested. Despite these efforts, few have made it to clinical use, the compounds 
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have not shown stronger anti-tumor effects than their forerunners, and 
importantly, none of the newer analogs has substantially improved the cardiac 
safety profile42. 
The anthracycline-induced cardiotoxicity often manifests in the adult patient 
within one year after administration and is commonly associated with a dilated 
and hypokinetic cardiomyopathy leading to heart failure46. The cardiotoxicity is 
classified into three subtypes according to the time of onset: (1) Acute cardiac 
toxicity occurs during or immediately after initiation of doxorubicin treatment 
resulting in tachyarrhythmia’s, including sinus tachycardia, premature ventricular 
contractions, and ventricular tachycardia, as well as bradycardia. (2) Early 
cardiotoxic events develop within one year of exposure and is usually presenting 
as a dilated and hypokinetic cardiomyopathy leading to heart failure. (3) The late 
cardiac toxicity may develop one or several years after initial exposure, and can 
result in a life-threatening cardiomyopathy46-48. Anthracycline-induced 
cardiomyopathy is exponentially dose-dependent49 and children and adolescent 
seem to be more susceptible to the cardiotoxic effects50. These circumstances 
indicate that there are several mechanisms responsible for anthracycline-induced 
cardiotoxicity.  
Despite intense research, the exact mechanisms behind anthracycline-induced 
cardiotoxicity is not fully understood. As illustrated in figure 2, oxidative stress, 
due to excessive production of reactive oxygen species and an altered iron 
metabolism have been described as the main contributors to the cardiotoxicity, 
but also modulation of signaling networks involving DNA damage responses, 
cardiomyocyte survival, cardiac inflammation, and energetic stress are suggested 
as potential explanations51 (see figure 3). Further understanding of the 
mechanisms causing the anthracycline-induced cardiotoxicity is crucial in order to 
improve the therapeutic use of anthracyclines and to enable earlier detection of 
the cardiotoxicity to reduce the damage. 
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Figure 2. Traditional mechanistic view of anthracycline-dependent oxidative stress 
and cardiotoxicity. Anthracyclines, such as doxorubicin, affects iron homeostasis in cells on 
many levels. Doxorubicin and its metabolites interact with iron regulatory protein (IRP) affecting 
iron-responsive elements (IREs) in the mRNA of genes involved in iron metabolism, ultimately 
controlling their expression level. Consequently, the level of free iron increases in both cytosol and 
mitochondria leading to a doxorubicin-induced iron overload. On the other hand, ATP-binding 
cassette sub-family B member 8 (ABCB8), a mitochondrial iron export protein, reduces 
mitochondrial iron accumulation and prevents cardiotoxicity resulting from the iron overload. 
Another mechanism underlying doxorubicin-dependent oxidative stress is linked to the ability of 
the drug to directly interfere with the activity of NADPH oxidase and nitric oxide synthase (NOS), 
resulting in the production of reactive oxygen species. Reprinted from51, with permission from 
Elsevier. 
  
In vitro toxicity testing using human pluripotent stem cell derivatives 
10 
 
Figure 3. New players in anthracycline-induced cardiotoxicity. Doxorubicin induces the 
release of high-mobility group protein B1 (HMGB1) which targets Toll-like receptor 2 and 4 (TLR2 
and TLR4). These membrane receptors, influences the transcription factors NF-κ β  and GATA4, 
which promotes immune responses and inhibits cardiac gene expression. At the plasma 
membrane, doxorubicin also represses the activity of growth factor receptors, ErbB2 and ErbB4, 
as well as the β 2 adrenergic receptor (β 2AR), further inhibiting PI3K-dependent survival 
signaling. Interleukin-6-related cytokines, like leukemia inhibitory factor (LIF) and cardiotrophin-1 
(CT-1), protect cardiomyocytes against doxorubicin-induced apoptosis, through both PI3K and 
STAT3 signaling pathways. On the other hand, doxorubicin directly binds to topoisomerase 2β  
Top2β ) in the nucleus and by stabilizing this enzyme, causes continuous DNA break and prevents 
the DNA double helix from being resealed. Doxorubicin-dependent DNA damage activates p53 
pathway thus resulting in cardiomyocyte apoptosis. Notably, doxorubicin can influence p53-
dependent apoptosis through additional signals, e.g. by inhibition of histone deacetylase (HDAC) 
and inhibition of AMP-activated protein kinase (AMPK) activity. Reprinted from51, with permission 
from Elsevier. 
.  
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1.4 Human pluripotent stem cells 
Stem cells are defined as immature, unspecialized cells with the ability to divide 
and differentiate into specialized cell types. Human pluripotent stem cells (hPSC) 
have the ability of indefinite self-renewal and the potential of differentiate into 
virtually any cell type in the human body. Human PSC can be of either embryonic 
origin52 or be derived from the reprogramming of somatic cells53, 54. There is great 
potential in hPSC as a cell source for a variety of applications. They can provide 
model systems for the study of developmental biology and they can constitute a 
platform for various in vitro applications, such as disease specific models, for 
targeted drug studies, and as a tool for toxicological assessments. 
1.4.1 Human embryonic stem cells 
Human embryonic stem cells (hESC) were first isolated about two decades ago 
and are pluripotent stem cells derived from a fertilized egg52, 55 (see figure 4).  The 
fertilized egg is cultured until the blastocyst stage (4-6 days old) which then 
possesses an outer layer called trophoblast, which during normal embryonic 
development constitutes the placenta, and an inner cell mass, that subsequently 
give rise to the embryo. Using immunosurgery and/or enzymatic removal of the 
trophoblast, the inner cell mass is isolated and seeded into culture dishes coated 
with either feeder cells, e.g. fibroblast cells of human or animal origin, or 
extracellular matrix in a specific, defined cell culture medium52, 56. This procedure 
enables the cells to start propagate in their undifferentiated state. To ensure that 
the cells remain pluripotent and to avoid spontaneous differentiation, the cells 
need to be passaged, i.e. the cells are dissociated, diluted, and seeded into new 
culture dishes. When cultured on feeder cells, the hESC traditionally are passaged 
using mechanical passaging, where the colonies are cut and separated by hand and 
seeded into new culture dishes. This process can also be done enzymatically, 
which ensures a higher throughput and enables automated culture.  
To ensure that the cells truly are hESC, they undergo extensive characterization, 
including morphological assessment, telomerase activity, karyotyping, analysis of 
pluripotency status, and the presence of pluripotency-specific cell surface markers 
(e.g. Stage specific embryonic antigen 3 (SSEA-3), Stage specific embryonic 
antigen 4 (SSEA-4), TRA-1-60, TRA-1-81) and transcription factors (e.g. 
Octamer-binding transcription factor 3/4  (OCT3/4), NANOG, SRY (sex 
determining region Y)-box 2 (SOX2))56. To verify the pluripotent status of the 
cells, the cells undergo in vitro differentiation through the formation of embryonic 
bodies. The embryonic body formation stimulates spontaneous differentiation of 
In vitro toxicity testing using human pluripotent stem cell derivatives 
12 
the hESC and the pluripotency is verified by the presence of cell types originating 
from all three germ layers. Pluripotency is also analyzed in vivo through 
xenografting of hESC into animal hosts, such as severe combined 
immunodeficient (SCID) mice57. To confirm presence of human tissue from all 
three germ layers, the xenograft can be analyzed by histopathology or 
immunohistochemistry.  
The great potential and widespread use of hESC has, however, been hampered 
by the ethical concerns that follows with the origin and the derivation process of 
the cells. The destruction of an embryo during the derivation of hESC has led to 
the prohibition of work with hESC in some countries, and strictly regulated work 
in countries where the work is allowed. The ethical issues surrounding hESC 
resulted in a focus to derive hESC lines without the destruction of embryos58, 59. 
The promising technique was published in 200760 but did not result in a 
widespread use, most likely due to the coinciding derivation of the first hiPSC. 
1.4.2 Human induced pluripotent stem cells 
Human iPSC were first derived by several independent groups in 200753, 61, 62. 
Human iPSC, free of the ethical issues surrounding hESC, are derived from adult 
somatic cells by genetic reprogramming. The genetic reprogramming, more 
precisely the over-expression of 3-4 transcription factors, results in a reversal of 
the cell fate into cells with pluripotent stem cell features, see figure 4.  
The hiPSC possess the same characteristics as hESC when it comes to 
morphology and functionality, propagation potential, telomerase activity, 
presence of pluripotency markers, and differentiation capacity53, 63. The obvious 
difference between the two are the origin sources: hESC are derived from a 
blastocyst, while hiPSC are derived from adult cells. As hiPSC originate from adult 
cells it can result in a potentially modified genetic and epigenetic state of the 
hiPSC, which might influence the phenotype of the cells and their derivatives. 
This feature is appealing when it comes to the study of specific diseases. The 
generation of hiPSC from differentiated somatic cells of healthy donors and 
patients of inherited and acquired diseases, allows for the creation of ‘disease 
model’ cell lines, and enables relevant studies of specific diseases on a cellular and 
molecular level. Even though this highlights the great advantage with hiPSC, on 
the contrary the inherited genetic and epigenetic footprints from the donors 
might lead to misinterpretations of the results in e.g. a general screening of drug 
candidates64, 65. Furthermore, the derivation of hiPSC using viral vectors that 
integrate the genome could potentially influence the outcome of studies in hiPSC. 
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This, together with the potential baggage of mutations accumulated in the donor 
cell, constitutes the major disadvantages of hiPSC for various in vitro studies. 
However, the weakness of hiPSC related to the viral integration has to a large 
extent been eluded with the intense research and development of non-viral 
transfection methods66-70. 
 
Figure 4. Derivation of hESC and hiPSC. Human ESCs derived from the inner cell mass of 
a blastocyst and hiPSCs derived from somatic cells from a donor individual by genetic 
reprogramming. 
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1.4.3 Differentiation of human pluripotent stem cells 
One of the most attractive features of hPSC is their ability to differentiate into in 
principally all specialized cell types in the human body, as illustrated in figure 5.  
The differentiation is a complicated process and a successful approach has proved 
to be to try to mimic the normal embryonic development as close as possible. 
Culturing the cells on specific matrices in the presence of key growth factors and 
small molecules steer the cells to differentiate towards the cell type of interest. 
The complex differentiation protocols are influenced by many cell culturing 
parameters, and are dependent on precise timing, concentrations and 
combinations of growth factors and inhibitors to ensure an efficient 
differentiation.  
Recent years of intense research within the stem cell field has significantly 
increased the knowledge of cellular differentiation and numerous protocols that 
reports on the differentiation of hESC and hiPSC to e.g. cardiomyocytes, 
hepatocytes, beta-cells, and neurons have been published71-79.   
 
Figure 5. Pluripotency of hPSC. Differentiation of hPSCs towards cells from all three germ 
layers; endoderm, mesoderm, and ectoderm. Hepatocytes and cardiomyocytes have been the 
focus for the investigations in this thesis. 
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1.5 Systems biology – omics technologies 
Systems biology is often referred to as computational and mathematical modelling 
of complex biological systems. In contrast to the traditional reductionist research 
approach, where researchers try to identify important individual components of 
biological systems, systems biology deals with the integration of many individual 
components to create a holistic view of the biological system under study80. 
As a result of recent year’s dramatic increase in high-throughput experimental 
techniques and omics data, the field of systems biology has emerged 
tremendously. Today, systems biology covers methods to obtain, analyze, and 
integrate large datasets from multiple experimental sources including genomics, 
epigenetics, transcriptomics, and proteomics.  
Within the scope of this thesis, the major work has been focusing on 
transcriptomics and proteomics and the two major technologies used are 
microarray analysis and quantitative proteomics using liquid chromatography and 
tandem mass spectrometry (LC-MS/MS). 
1.5.1 Microarray 
The microarray technology is a high-throughput technology, introduced in the 
mid 1990’s81-83, that enables examination of more or less the complete gene 
expression in a sample at a specific time point. The microarray technology is based 
on the base paring between DNA and RNA. When complementary strands of 
DNA and RNA meet, they will join together in a hybridized state. The microarray 
consists of a surface, usually plastic or glass, with spots of short immobilized 
DNA strands (cDNA or oligonucleotides) attached to it84. Each spot, or probe, 
corresponds to a specific transcript and consists of a large number of copies of 
the same DNA strand. Due to the large number of probes on an array, one 
microarray or a set of microarrays can be used to evaluate the complete mRNA 
(or microRNA) expression in a cell- or tissue sample84.  
The initial process of a microarray analysis is to extract the total RNA from a 
biological sample, a critical step of the process since the microarray analysis is 
dependent on high quality RNA. The extracted RNA is subjected to rigorous 
quality controls before entering the general processing for microarray analysis.  
The standard procedures for microarray analysis differ slightly depending on 
platform used, but most often include the following series of steps85. It starts with 
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amplification of the material, sometimes including a conversion of the RNA to 
more stable cDNA, and the amplified RNA or cDNA is labelled with a 
fluorescent dye. There are two main types of arrays, one-channel arrays and two 
channel arrays. For one-channel arrays one fluorescent dye is used for labelling 
and only one sample can be hybridized on each array. For two-channel arrays, 
two fluorescent dyes (with two different emission wavelengths) are used and two 
samples are labelled and hybridized to the same array. The microarray is then 
exposed to the fluorescently labelled RNA or cDNA and if the transcripts find 
complementary DNA probes it will hybridize. After a number of subsequent 
washing and drying procedures of the array to remove non hybridized 
RNA/cDNA, the array is scanned using a scanning system equipped with a laser 
device.  
The scanning of the array measures the fluorescent intensities in each spot, which 
correspond to the number of bound transcripts, and represent the expression 
level of that particular gene. Subsequently, the scanned images are transformed to 
expression values. This process is supported by software included in the scanning 
device. Next, it is time for low level analysis including handling of missing values, 
background correction, normalization, and log transformation of the data. The 
background correction is essential to acquire noise-reduced values, and the 
normalization is needed to reduce the systematic variation and to separate true 
biological variation from experimental bias. The normalization process can be 
done between arrays, within individual arrays, and for the dye-labelled channels 
on two-channel arrays. The resulting pre-processed dataset is now ready for the 
high level analysis, where the biologically meaningful information will be extracted 
from the dataset. This part is discussed in detail in the following method section. 
1.5.2 Quantitative proteomics 
In recent years, there has been great advances in mass spectrometry-based 
proteomics and it is now possible to measure several properties, such as the 
protein abundance, turnover rate, subcellular localization, and post-translational 
modification, for thousands of proteins. For the studies in this thesis the 
abundance of proteins has been measure using LC-MS/MS together with labeling 
of isobaric tags (Tandem mass tags – TMT™, Thermo Fischer Scientific)86. The 
technology is based on the use of LC as a separation tool for proteins (or peptides) 
with subsequent repeated steps of mass spectrometry to identify and quantify the 
separated proteins or peptides. The strategy used is a so called “bottom-up” 
approach, where the proteins, in a first step, are cleaved by the endopeptidase 
trypsin into peptides, which solely constitute the subjects for the MS/MS 
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analysis87. The digested peptides are separated using LC, before subsequent 
analysis by MS. In direct connection to the LC instrument, is a mass spectrometer, 
which measures the mass-to-charge ratio of charged particles, in order to 
determine the mass of the particles. The separated peptides are loaded into the 
MS instrument and vaporized before being ionized by an ion source, in this case 
electrospray ionization. In the mass analyzer the ions, i.e. the charged peptides, 
are separated by their mass-to-charge ratio using electromagnetic fields, before 
the detector quantifies the ion signals and convert it to a mass spectra. The 
information from a mass spectra is usually not sufficient for the identification of 
a peptide since these signals are not unique for a peptide87. Therefore, it is 
necessary to perform a tandem MS. The first MS step is performed to determine 
the mass of the intact peptide, the precursor ion. In the second MS step the 
precursor ion is isolated from other peptides ions, dissociated into fragments and 
the masses of the fragments are determined. In the case of TMT™ labelled 
peptides, one additional fragmentation, and a third MS is performed to dissociate 
and quantify the TMT™ reporter ions.  
To determine the abundance of proteins in a sample, either as absolute values or 
relative the amount of the protein in another sample, different techniques have 
been developed. Many of these methods involve the labelling of proteins with 
stable isotopes. The general procedure is to tag samples containing proteins or 
peptides with reagents with various tag variants. The samples are mixed prior to 
the MS analysis and the resulting peaks in the mass spectra reveal the ratio of the 
different tag variants and can be used to determine the relative abundance of each 
protein or peptide. The TMT™ reagent from Thermo Scientific constitute one 
method of isotopic labelling for relative quantification86. The TMT™ allows for 
the multiplexing of up to ten samples in a single run, and consist of different 
isobaric (same molecular weight) tags that are based on the same chemical 
structure. The tags contain a tag-specific reporter group and a mass normalizer 
group that leads to an equal overall mass for the different tags. During the 
fragmentation for the MS3 the reporter groups are cleaved and creates up to ten 
different signals, the relative intensities of these signals represent the ratios of the 
corresponding ten samples. Accurate, high-resolution mass spectrometer 
analyzers allow for the separation between these reporter ion isotopes and enable 
increased multiplexing for relative quantification and increased sample 
throughput88. In addition, using one of the tags for a reference sample allows for 
the comparison between TMT™ sets, increasing the throughput even further. 
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2 AIMS OF THE THESIS 
The overall aim of this thesis is to investigate if hepatocytes and cardiomyocytes 
derived from hPSCs can be used as in vitro models for drug-induced toxicity 
studies and assessment. 
2.1 Specific aims 
 To explore the feasibility of using hPSC-derived hepatocytes 
(addressed in paper I) and cardiomyocytes (addressed in paper 
II) to study toxic drug exposure for up to two weeks.  
 To investigate if large scale omics data and bioinformatics tools 
can be used to evaluate the cellular responses to doxorubicin 
(addressed in paper II-IV). 
 To further explore the cellular responses to doxorubicin and 
identify potential biomarkers of the compound-induced toxicity 
(addressed in paper II-III). 
 To investigate underlying mechanisms involved in doxorubicin-
induced cardiotoxicity by integration of data from mRNA, 
microRNA, and protein expression (addressed in paper IV). 
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3 METHODS 
3.1 Differentiation of hepatocytes and 
cardiomyocytes 
The work in this thesis was performed in collaboration with Takara Bio Europe 
AB (former Cellartis AB), a biotechnology company with long standing 
experience in deriving, culturing, and differentiating hPSC. The thesis work has 
not included the development of differentiation protocols for the different cell 
types studied and has, as far as possible, been conducted with established, 
published protocols or commercially available cell types and kits for 
differentiation. However, the handling of the cells, related to timing, seeding 
densities, and culture formats, has been adapted, to ensure optimal conditions for 
the toxic drug exposure and subsequent analyses. The hepatocytes used were 
generated from hiPSCs, and the cardiomyocytes were derived from a hESC line. 
The details about the cell cultures can be found in papers I-IV. 
3.2 Cell characterization 
The hepatocytes and cardiomyocytes used in this thesis are extensively 
characterized during the establishment of the differentiation protocols, and this 
has been reported elsewhere15, 89, 90. The main aim of this thesis was not to 
characterize the cells as such, but rather to investigate potential applications of 
the cells. However, some basic characterization, consisting of assessment of 
important cell type-specific proteins and functions, to ensure relevant phenotypes 
of the cells has been performed. For the hepatocytes, morphological evaluation 
of the cells, their ability to store glycogen (by Periodic acid Schiff staining), and 
the presence of cytokeratin 18 and hepatocyte nuclear factor 4a, was reported 
(Paper I).  
Correspondingly, for the cardiomyocytes, morphology evaluation together with 
immunocytochemistry of cardiac specific troponin (cTnT), NK2 Homeobox 5 
(NKX2.5), and Myosin regulatory light chain 2, atrial isoform (MLC2a), was 
reported (Paper II). 
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3.3 Incubations with toxicants 
The study described in paper I, was designed to investigate the toxic exposure of 
drugs in hiPSC-derived hepatocytes during a two week time period. Four 
compounds known to be toxic to hepatocytes were chosen; Amiodarone, 
Aflatoxin B1, Troglitazone, and Ximelagatran, which all possess different modes-
of-actions for their toxicity. All compounds were dissolved in dimethyl sulfoxide 
(DMSO) and were subjected to half-logarithmic serial dilutions (in DMSO), to 
ensure precise dilutions over large concentration spans. A second dilution of the 
concentration series, prior to the exposure to the cells, were performed in cell 
culture medium to reduce the final concentration of DMSO to 0.4% and to be 
able to monitor any potential precipitation of the compounds. The highest assay 
concentrations were chosen based on the properties of the compounds and 
relevance to the clinical situation. Stem cell derived hepatocytes, differentiated for 
approximately three weeks, were exposed to the compounds, in a repeated-dose 
regime, over a two week time period, with medium changes every second day. 
Appropriate untreated control cells were cultured in parallel.  
For the studies reported in paper II – IV, stem cell derived cardiomyocytes were 
exposed to doxorubicin at various concentrations during two days, followed by a 
recovery period of 12 days without doxorubicin. This regime was chosen with the 
rational to study both the acute toxic phase of doxorubicin as well as potentially 
remaining effects of the exposure. Initial pilot studies, conducted prior to the first 
study reported in paper II, indicated that a doxorubicin concentration up to 450 
nM affects the cardiomyocytes (based on measurements of cTnT release from the 
cells) without causing substantial general cytotoxicity (judged by viability 
assessment). A concentration of 450 nM correlates well to the peak plasma 
concentrations seen during clinical use of doxorubicin91, 92. Two additional 
concentrations of doxorubicin (50 nM and 150 nM) were included, in order to 
study dose-dependent effects. Doxorubicin was dissolved in DMSO followed by 
a dilution step in cell culture medium to a final DMSO concentration of 0.05%. 
3.4 Viability and cytotoxicity 
3.4.1 EZ4U 
There are several ways to measure the number of cells in cultures. Direct 
measurements include e.g. microscopic inspection or the use of an electronic 
particle counter, and there are indirect means such as the measurement of 
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incorporated radioactive markers, quantification of total protein content, or 
measurement of metabolic activity of cellular enzymes.  
The proliferation and cytotoxicity assay used in paper I, EZ4U (Biomedica 
immunoassays), is based on the findings that viable cells are capable to reduce 
weakly colored tetrazolium salts into intensely colored formazan derivatives. This 
process requires functional mitochondria, which are inactivated within a few 
minutes in dead cells. The EZ4U assay contains a non-toxic tetrazolium salt that 
can be reduced to soluble, colored derivate that indirectly correlates to the number 
of viable cells in the sample. The assay is recorded in a microplate-reader by 
measuring the absorbance at a specific wavelength (450 or 492 nm) in each well. 
3.4.2 Steatosis and Phospholipidosis 
To assess the induction of steatosis and phospholipidosis in the hepatocytes 
following compound exposure, the cells were stained with fluorescent probes for 
neutral lipids (HCS LipidTOX Green Neutral Lipid, www.thermofischer.com) 
and phospholipids (HCS LipidTOX Red Phospholipidosis, 
www.thermofischer.com) and analyzed in an automated manner using 
ImageXpress Micro (Molecular Devices, Sunnyvale, CA). The fluorescent probe 
works as a signaling flag for the target of interest. One part of the probe has a 
high affinity to bind to the target, in this case neutral lipids and phospholipids, 
and another part of the probe acts as a fluorophore. The fluorophore works by 
absorbing light from an external light source, the excitation light, and send out 
light of another wavelength. The emitted light is detected in a fluorescent 
microscope or an automated high-content screening device. Using image analysis 
software, the labelling of the cells can be quantified and reported as e.g. a 
percentage of positive cells within the cultures. 
3.4.3 Lactate Dehydrogenase 
Cytotoxic effects in cells are usually associated with damage to the cell membrane. 
This can be assessed by monitoring the extracellular leakage of intracellular 
substances that are normally seized inside cells. Lactate dehydrogenase (LDH) is 
an intracellular enzyme that catalyzes the conversion of pyruvate and lactate and 
is present in all cell types. Since LDH is a relatively stable enzyme, it has been 
widely used to evaluate the presence of damage and toxicity of tissue and cells93, 
94.  
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For the work in this thesis, LDH leakage was measured in conditioned culture 
medium after the cardiomyocytes had been exposed to doxorubicin, as an 
indicator of general cytotoxicity within the cultures. 
3.4.4 Cardiac-specific troponin 
Troponins are regulatory protein involved in Ca2+-mediated processes of 
contraction and relaxation of muscles. Troponin consists of three subunits C, T, 
and I, which interact with different parts of the actin/tropomyosin filaments. 
Each subunit exists in several isoforms that are encoded by separate genes and 
they can be distinguished by immunological techniques. Troponin T and I both 
have isoforms that are specific for cardiomyocytes, and are therefore suitable as 
markers for cardiac injury95. Cardiac troponin is also a widely accepted and 
clinically used biomarker in humans for cardiac injury due to ischemic injury and 
drug toxicity. It is highly correlated to extent of injury, deficiency of cardiac 
function, and prognosis96. It is also considered a highly translational biomarker 
and its usage to detect myocardial damage in pre-clinical pharmacology, 
toxicological studies, and animal studies is quickly growing95.  
For the studies in this thesis (paper II), cTnT was measured in conditioned culture 
medium, after the cells were incubation with doxorubicin, as a sign of cardiac-
specific toxicity. The cTnT was measured using an automated immune-
chemiluminiscence instrument and the high sensitive Troponin T assay (Elecsys, 
Roche). 
3.5 Microarray analysis 
A key element for the work in this thesis was to use large scale omics data to 
evaluate the stem cell-derived in vitro models. Global microarray experiments have 
been conducted in order to generate extensive transcriptional datasets. For the 
project two different microarray platforms were used: 
 GeneChip® Human Gene 2.0 ST Array (Affymetrix, Santa 
Clara, CA) 
 miRCURY LNA™ microRNA Array 7th Gen (Exiqon, 
Denmark) 
Gustav Holmgren 
25 
3.5.1 Microarray experiment in paper II 
The first study using hESC-derived cardiomyocytes, described in paper II, was 
designed to evaluate the cells’ response to doxorubicin at the transcriptional level. 
As described in 3.3, the cardiomyocytes were exposed to doxorubicin in three 
different concentrations for up to two days, followed by a recovery period of an 
additional 12 days. At selected time points during the study, day 0, 1, 2, 7, and 14, 
cells were harvested and total RNA was isolated using Qiagen’s RNeasy Plus 
Micro Kit (www.qiagen.com) according to the manual. The experiment, including 
untreated controls, was run in triplicates resulting in a total of 51 samples collected 
and subjected for microarray analysis with GeneChip® Human Gene 2.0 ST 
Array (Affymetrix, Santa Clara, CA). Following RNA quality assessment, the 
samples were hybridized to the microarrays. Using the Expression Console v.1.1.2 
(Affymetrix), the expression signals were normalized using the robust multichip 
average (RMA) normalization method resulting in log2 transformed data, which 
was subjected to succeeding high-level data analysis. SCIBLU Genomics Core 
Facility at Lund University performed all the low-level analysis until the 
normalization step. 
3.5.2 Microarray experiment in paper III 
The study described in paper III aimed to evaluate the microRNA expression in 
hESC-derived cardiomyocytes following doxorubicin exposure. The same 
experimental setup as the mRNA experiment described in paper II was applied 
here, using the same concentration and sampling parameters. However, total 
RNA was isolated using GenElute RNA/DNA/Protein plus Purification Kit 
(E5163, Sigma-Aldrich, Sweden, http://www.sigmaaldrich.com), for 
simultaneous isolation of protein from the same samples. This isolation kit also 
allows the preservation of all RNA, including the small microRNA. After 
assessment of RNA quality, samples were hybridized to the miRCURY LNA™ 
microRNA Array 7th Gen (Exiqon, Denmark). This array is a two channel array, 
hence the samples are labeled with one fluorescent label (Hy3™) and a RNA 
reference is labeled with the second fluorescent label (Hy5™) prior to 
hybridization. After scanning and image analysis of the microarrays, the quantified 
signals were extracted, background corrected, and normalized using the global 
locally weighted scatterplot smoothing (LOWESS) regression algorithm. 
Detected microRNAs with low intensities (below the threshold for each array) in 
more than 80% of the samples were filtered prior to subsequent expression 
analysis. All microarray analysis, from RNA quality control up until expression 
analysis, was conducted at Exiqon Services, Denmark. 
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3.6 Quantitative proteomics 
A major focus for paper IV in this thesis was to investigate the responses to 
doxorubicin in the hESC-derived cardiomyocytes on the protein level. The 
microRNA experiment (described in paper III) was designed to enable for the 
simultaneous acquiring of total protein samples. The protein samples were 
subjected for a relative quantification using isobaric tag-labeling and LC-MS/MS 
analysis.  
All protein samples together with a reference pool (containing aliquots from all 
sample groups) were processed for protein reduction, alkylation, and digestion. 
The resulting peptides were subjected to isobaric mass tag labelling with TMT™ 
reagent according to the manufacturer’s instructions (Thermo Scientific). The 
TMT™-labeled samples were analyzed using LC-MS/MS and the subsequent raw 
data files were entered into Proteome Discoverer version 1.4 (Thermo Fisher 
Scientific) for protein identification and relative quantification. Only peptides 
unique for a given protein were considered for relative quantitation, and only 
proteins that were detected in all samples by all three replicates were considered 
for further analysis. All described work after the isolation of protein samples, until 
the analysis of the proteomics data, was conducted at the Proteomics Core Facility 
at Sahlgrenska Academy, Gothenburg University. 
3.7 Bioinformatics and statistical analysis 
The analysis of the data generated by microarray analysis and protein 
quantification can be divided into low-level analysis and high-level analysis. Low-
level analysis can vary depending on analysis platform but can be described as the 
pre-processing of the raw data to ensure a valid dataset for the subsequent 
analysis. The pre-processing often includes: filtering procedures, i.e. removal of 
bad quality data e.g. bad spots on a microarray; handling of missing values; 
normalization to remove systemic, non-biological variation; and log 
transformation of the data.   
For the high-level analysis, in order to extract relevant biological information 
from the extensive data, advanced bioinformatics algorithms are required. The 
important bioinformatics analyses used for this thesis are described below. 
The majority of the analyses within this thesis was carried out using the free R 
software environment (www.r-project.org), a programming language and 
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environment for statistical computation and graphics. The R environment 
provides a wide range of statistical and graphical techniques, has a large collection 
of tools for data analysis, and is highly extensible via the concept of different 
‘packages’. 
3.7.1 Identification of differential expression 
One important part when analyzing large scale omics data is to identify differential 
expression, i.e. genes or proteins that are induced or repressed under a specific 
condition or in a particular biological process. This was of relevance in the study 
of doxorubicin-induced toxicity in the hESC-derived cardiomyocytes, where a 
major goal was to identify significantly affected mRNAs, microRNAs, and 
proteins.  
There are many different methods to identify differential expression. Simple 
methods, such as average fold change, where genes are considered to have 
differential expression if the fold change between two samples, e.g. between case 
and control samples, are above a certain threshold. One common method is to 
use statistical significance to decide on differential expression, e.g. perform T-
tests and use a p-value threshold for significant differences. When analyzing many 
genes with these types of methods it is important to consider the multiple testing 
problem, and the risk of identification of many false positives. These methods 
therefore require correction of the p-values for multiple testing.  
There are also more specialized statistical tests developed for certain applications. 
For the analyses of the microarray data in paper II and III, the Significance 
Analysis of Microarray Data (SAM)97 have been applied. SAM is included in the 
Siggenes package available in R (http://www.bioconductor.org), and identifies 
differentially expressed genes in microarray data, by controlling the false discovery 
rate, i.e. the percentage of genes identified by chance. Briefly, the method assigns 
a score to each gene based on the difference between samples, in relation to the 
standard deviation of repeated measurements. The false discovery rate is 
determined using permutations of the repeated measurements. 
The SAM was developed for microarray data, but for the study in paper IV the 
intent was to integrate the results from the different omics data, and it is desirable 
to identify differential expression in the diverse sets of data using the same 
method. Thus, the f-divergence cutoff index (fCI) model was used, since it was 
developed with the purpose to identify differential expression across different 
omics data types and multi-dimensional data98.  
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Briefly, the fCI model creates control-control and control-treatment 
combinations and compares the similarity of the ratio distributions for the 
different combinations. If the treatment causes upregulation or downregulation 
of certain genes, the distribution of the ratios from control-treatment pairs 
compared to the control-control (empirical null) distribution will appear different. 
To identify differentially expressed objects (genes or proteins), the difference 
between the distributions is quantified by a function called f-divergence. The fCI 
model uses a mathematical function called the Hellinger distance to calculate the 
f-divergence, and objects are removed from both tails of the control-treatment 
distribution until the remaining distribution is similar or identical to the empirical 
null distribution. The removed objects are classified as dysregulated and the 
analysis output contains a list of the dysregulated objects for all the pairwise 
analysis results, including the total number of times an object is found to be 
dysregulated and the coverage percentage. 
3.7.2 Cluster analysis 
Data from microarray and quantitative proteomic experiments consists of loads 
of disperse information and in order to reduce the number of dimensions and 
facilitate the data interpretation there are many different clustering techniques 
available. The purpose of clustering is to organize the data, to highlight what 
contributes to the variation seen in the data, and to identify co-expressed and 
related genes/proteins. For this project, several different methods have been 
used, depending on the intention of the clustering.  
Principal component analysis (PCA)99, 100 and agglomerative hierarchical 
clustering101 have, in this project, mainly been performed on a global scale, on 
whole data sets, with the aim to assess that the samples cluster in a biologically 
relevant way. One purpose was to identify outliers and to assure that the 
experiment worked out as anticipated.  
PCA is a statistical technique to reduce the dimensionality of large data sets and 
make the data more interpretable. Large data set consists of many related variables 
and PCA transforms the data into uncorrelated variables, so called principal 
components, which are ordered in such a way that the first component accounts 
for as much variability in the data as possible99. A PCA plot indicates if your 
samples are separated in a biologically relevant manner and elucidate relationships 
in your samples depending on how they cluster.   
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Agglomerative hierarchical clustering101 also investigates relationships in the data. 
The method starts with each object as a separate cluster and gradually link and 
merge objects into clusters based on a distance measurement. The result is a 
dendrogram, showing the relationship between the samples, where the branches 
represent similarity.  
As the name suggests, the hierarchical clustering has a hierarchical approach to 
group objects into larger clusters. The alternative is to use partitional clustering, 
where the most common method is the K-means algorithm. K-means was 
developed over 50 years ago, and due to its ease of implementation, simplicity, 
and efficiency, it is still one of the most widely used algorithms for clustering102.   
There are many different methods to measure the distance, or similarity, between 
to objects (genes/proteins) or clusters. The main method used for this project is 
the Pearson correlation, or Pearson Product Moment Correlation. Pearson 
correlation considers the ‘shapes’ of expression profiles to calculate the similarity 
between objects. One advantage of this method is that genes with similar 
expression profiles but large differences in expression level will still be judged as 
similar. 
3.7.3 Pathway analysis 
Pathway over-representation analysis (ORA) has been performed within the 
scope of this thesis. The aim of a pathway ORA is to analyze whether lists of 
differentially expressed genes and/or proteins are significantly associated with a 
particular signaling pathway or set of pathways, and to further interpret the 
biological meaning of identified differentially expressed genes and/or proteins.  
For the ORA of differentially expressed mRNA and proteins found in this 
project, the database ConsensusPathDB103-105 have been used. ConsensusPathDB 
is a database that integrates different types of functional interaction data of 
currently 32 resources and databases (Release 31, 01. Sept. 2015). Over-
represented sets of genes are searched for in predefined gene sets, of e.g. pathway 
or Gene Ontology category. For each predefined set a p-value is calculated with 
a hypergeometric test based on the number of physical entities (i.e. genes or 
proteins) in the predefined set and the user-specified input list. The p-values are 
corrected for multiple testing using the false discovery rate method (q-value) and 
the output of the analysis is a list of all sets whose hypergeometric tests p-value 
passes the threshold set by the user.  
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The ConsensusPathDB described above is developed for physical entities, such 
as lists of genes or proteins, however, with the increasing interest and knowledge 
about microRNAs the need for similar tools for microRNAs is increasing rapidly. 
In this aspect, the software tool microRNAs enrichment analysis and annotation: 
miEAA, was developed106. Like many similar web-based application, miEAA 
offers the common statistical tests, such as ORA and Gene Set Enrichment 
Analysis (GSEA), but with the exception that it is tailored for microRNAs or 
microRNA precursors as input. The miEAA application calculates significance 
for a test set to be over- or underrepresented in respect to a reference set and uses 
Fischer’s exact test to compute p-values. Similar to the ORA in 
ConsensusPathDB, the p-values are corrected for multiple testing and the user 
can define specific thresholds for significance. 
3.7.4 Integration of omics data 
With the advances in technologies to generate large scale data on various 
molecular levels there is a growing demand for cross-platform dataset analysis. 
The application: Integrated analysis of Cross-platform MicroArray and Pathway 
data (InCroMAP), was developed for this purpose, and offers a powerful, easy-
to-use high-level cross-platform microarray dataset analysis tool107, 108. 
InCroMAP, which is freely available as a Java application, can be used for 
pathway-based analysis and visualization of heterogeneous, cross-platform 
datasets.  
The user inputs processed datasets, i.e. calculated fold change values or p-values, 
of any or all of the currently supported platforms: mRNA, microRNA, DNA 
methylation, and protein modification, and a variety of different methods for the 
integrated analysis of data from these platforms are available.  
For the study described in paper IV, InCroMAP was used to visualize the 
expression of the various datasets in several selected pathways. The basis for the 
visualization are imported from the Kyoto encyclopedia of Genes and Genomes 
(KEGG) database, and consists of a background image of the selected pathway. 
This background image is overlaid with nodes representing mRNAs, proteins, and 
microRNAs involved in the pathways. To visualize the expression values, the 
nodes are colored according to a color gradient ranging from blue through white 
to red to illustrate down- and upregulation. Non-differentially expressed genes are 
shown in white, and pathway nodes for which no input data are available are 
displayed in grey. 
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4 RESULTS IN SUMMARY 
4.1 Paper I: Long-Term Chronic Toxicity Testing 
Using Human Pluripotent Stem Cell–Derived 
Hepatocytes 
In paper I, the utility of hPSC-derived hepatocytes for hepatotoxicity studies was 
assessed. Existing hepatic in vivo and in vitro models show clear limitations when it 
comes to accessibility, functionality, resemblance to in vivo situation, and 
particularly possibility to be used for longer time periods. For these reasons, the 
aim of the first study was to assess long term exposure of hepatotoxic drugs in 
the hPSC-derived hepatocytes. The hiPSC-derived hepatocytes (hiPS-HEP) were 
exposed to various concentrations of known hepatotoxic compounds for up to 
14 days, following a repeated dose regime. Besides monitoring the cell 
morphology, the cells sensitivity to the compounds was assessed using the EZ4U 
cell proliferation and cytotoxicity assay (Biomedica/Biotech-IgG, Copenhagen, 
Denmark). In addition, specific toxicity was assessed by quantification of the 
induction of steatosis and phospholipidosis within the cells using automated 
imaging and analysis. The results demonstrate that the cells are sensitive to several 
of the compounds, since a clear dose-dependent decrease in viability was 
observed for amiodarone, aflatoxin B1, and troglitazone. The cells also 
demonstrated an increased sensitivity to these compounds during the long term 
exposure, as indicated by a significant shift in the dose-response curves for the 7- 
and 14-days exposures compared to the single dose 2-day exposure. To assess 
whether the cells responded to the compounds in a hepatocyte-relevant manner, 
the cells were exposed to sub-cytotoxic concentrations (10% effective 
concentration at 14 days exposure) of the compounds, and stained for steatosis 
and phospholipidosis. The results reveal an induction of steatosis and 
phospholipidosis in the cells when exposed to amiodarone and troglitazone, 
respectively. Most importantly, this study demonstrates that the hiPS-HEP can 
be derived in a robust manner and that the cells are stable enough to constitute 
an in vitro cell model that enables a two-week exposure study of hepatotoxic 
compounds. 
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4.2 Paper II: Identification of novel biomarkers for 
doxorubicin-induced toxicity in human 
cardiomyocytes derived from pluripotent stem 
cells 
The study described in paper II was designed to assess the utility of hPSC-derived 
cardiomyocytes for cardiotoxicity studies over a two week time period. 
Doxorubicin, a chemotherapeutic drug with well-known cardiotoxic effects, was 
chosen as the toxic model compound to study. Doxorubicin demonstrates a dose-
dependent cardiotoxicity with a multifactorial etiology, and despite being intensely 
studied for several decades, the exact mechanisms behind the toxicity remain 
unrevealed. The hESC-derived cardiomyocytes were exposed to a single dose of 
doxorubicin at various concentrations (50 nM, 150 nM, and 450 nM) for up to 
two days, followed by an additional study period of 12 days without doxorubicin. 
This experimental design enables the study of both the acute toxic response as 
well as the study of sustained effects of the drug. At selected time points 
throughout the study (at day 0, 1, 2, 7, and 14), the morphology of the 
cardiomyocytes were monitored, in connection to the measurement of LDH and 
cTnT release from the cells, as indications of general and cardio-specific 
responses to the toxic insult. To get an in-depth understanding of the mechanisms 
involved in the doxorubicin-induced toxicity, the global transcription within the 
cells were analyzed using microarray technology. The experiments show that the 
hESC-derived cardiomyocytes are robust and stable enough to enable a two-week 
study of drug-induced toxicity. The results of the study further demonstrate a 
clear effect of doxorubicin already after one day of exposure. The cells displayed 
an altered morphology and reduced contractility, and these effects were sustained 
throughout the entire study. A general cytotoxicity could be observed during the 
acute exposure by elevated leakage of LDH at day two in treated cells compared 
to controls. A similar dose-dependent pattern could be observed for the cTnT 
release from the cells during day one and day two of exposure. However, despite 
a clear morphological and functional effect of doxorubicin during the recovery 
period, no elevated release of neither LDH nor cTnT could be observed during 
this period, suggesting that these markers might not be suitable as biomarkers for 
the late onset of doxorubicin-induced cardiotoxicity. The global transcription 
analysis reveal an evident effect of doxorubicin on the transcriptional level.  
Hierarchical clustering of the global mRNA expression shows a clear separation 
of the samples into six distinct groups, which correlated to the time factor and 
treatment of the groups. Investigations of dysregulated genes upon doxorubicin 
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exposure were carried out with the statistical method SAM and the simplified 
approach of gene expression profile search, and revealed lists of dysregulated 
genes with high concordance between the two approaches. Further analysis of the 
differentially expressed genes shows connection of cellular defense and the p53-
signaling pathway. Some of the differentially expressed genes, such as Growth 
Differentiation Factor 15 (GDF15), Neurofilament, Light Polypeptide (NEFL), 
LDL Receptor Related Protein Associated Protein 1 (LRPAP1), Family with 
Sequence Similarity 198 Member B (FAM198B), RAD15 paralog C (RAD51C), 
and Growth Arrest and DNA Damage Inducible Alpha (GADD45A), 
demonstrate elevated expression for the treated samples compared to the controls 
throughout the entire experiment, which might indicate a potential role for these 
genes as biomarkers for doxorubicin-induced cardiotoxicity. 
4.3 Paper III: MicroRNAs as potential biomarkers 
for doxorubicin-induced cardiotoxicity 
As a follow-up to the study reported in paper II, the subsequent experiment was 
designed to elucidate the involvement of the regulatory network of microRNAs 
in the doxorubicin-induced cardiotoxicity. Additional aims of this study were to 
identify microRNAs as potential biomarkers for the toxicity, to further strengthen 
the utility of hPSC-derived cardiomyocytes as a relevant in vitro model, as well as 
to evaluate the use of large-scale data and bioinformatics for these purposes. The 
cardiomyocytes were subject to the same experimental procedure as in paper II 
and isolation of total RNA for microRNA profiling was performed. Using 
microarray technology, the global expression of microRNAs was analyzed. 
MicroRNAs have in recent years been shown to have a great potential as clinical 
biomarkers, due to their high evolutionary conservation, stability in various body 
fluids, and in general a high cell type or tissue specificity. The results from this 
study reveal a clear effect of doxorubicin on the global microRNA expression. 
Principal component analysis and hierarchical clustering of the global microRNA 
expression show a separation of the samples by both the time and the treatment 
factor, indicating that the cells respond to the doxorubicin treatment in a 
biologically relevant way. Using SAM, we identified several microRNAs, including 
miR-34a, miR-34b, miR-187, miR-199a, miR- 199b, miR-146a, miR-15b, miR-
130a, miR-214, and miR-424, which are differentially expressed upon, and after, 
treatment with doxorubicin. The majority of the microRNAs that show a 
sustained effect during the wash-out period are dose-dependently downregulated. 
To investigate the biological relevance of the dysregulated microRNAs, pathway 
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ORA was performed and revealed a connection to pathways related to 
cardiomyocytes and heart function, apoptosis, inflammatory responses, and 
cellular defense mechanisms. Three microRNAs show a sustained upregulation 
upon doxorubicin treatment throughout the whole experiment, which make them 
very interesting as potential biomarkers for the toxicity. Both miR-34a and miR-
34b have previously been shown to be associated with pathological situations in 
the heart, while miR-187 has been associated with cancer and inflammatory 
pathways. In summary, the results reported in paper III identify a clear effect of 
doxorubicin on the microRNA expression with a high correlation to the impaired 
cardiomyocyte function. Several microRNAs are identified as potential 
biomarkers for the doxorubicin-induced cardiotoxicity. 
4.4 Paper IV: Expression profiling of human 
pluripotent stem cell-derived cardiomyocytes 
exposed to doxorubicin – integration and 
visualization of multi omics data 
Protein expression represents the functional counterpart of the mRNA 
expression and in that sense might illustrate the events taking place in the cells in 
a more precise way. Recent advances in the mass spectrometry-based proteomics, 
using for instance covalently bound chemical tags such as TMT™s allow for the 
relative quantification of many proteins in biological samples simultaneously.    
The microRNA experiment reported in paper III was designed for the parallel 
harvest of proteins from the same samples, thus 51 samples were subjected for 
relative quantification using LC-MS/MS with isobaric TMT™ labelling. The 
results were assessed on a global scale and PCA of all samples demonstrate a 
relevant separation of the samples both by the experimental time factor and the 
treatment. Differentially expressed proteins were identified with the fCI model, 
which revealed a clear dose dependent increase in the number of differentially 
expressed proteins at each time point. In total, the fCI method identified 199 
unique proteins that showed differential expression in at least one treatment 
group compared to the controls during at least one time point. Amongst the 
identified differentially expressed proteins, we observed proteins related to 
myofibrillar function such as the myosin light chain family (MYL2, MYL3, MYL4, 
MYL6, MYL7, and MYL12A), myosin heavy chain (MYH7, MYH9, MYH10), 
troponins (Troponin C1 (TNNC1), Troponin I3 (TNNI3), and Troponin T2 
(TNNT2)), and tropomyosin (TPM1, TPM2, and TPM4); ribosomal proteins; 
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mitochondrial associated protein such as the cytochrome C oxidase (COX) 
family, and adenosine triphosphate (ATP) family, and proteins linked to reactive 
oxygen species formation such as Tumor Protein P53 Inducible Protein 3 
(TP53I3). KEGG pathway ORA of the identified differentially expressed proteins 
revealed a clear connection to cardiomyocyte related pathways, such as cardiac 
muscle contraction, hypertrophic cardiomyopathy, and dilated cardiomyopathy. 
K-means clustering was used to identify clusters of differentially expressed 
proteins with different expression profiles. There are proteins connected to cell 
communication and mitochondrial apoptosis signaling that show an early 
upregulation due to the doxorubicin treatment. Clusters that are downregulated 
upon doxorubicin exposure are found to be related to cardiomyocyte function 
and contraction as well as there are clusters, also connected to the cardiomyocyte 
function, that display an upregulation over time.  
An additional aim with this study was to, in a more in-depth manner, investigate 
how doxorubicin influences the cardiomyocyte functionality by integrating the 
findings from the proteomics data with the previously generated transcriptomics 
data reported in paper II and III. To enable an integration of the different levels 
of data, the mRNA and microRNA data were re-analyzed for differential 
expression using the fCI model, thus using the same approach as for the protein 
data. This resulted in 7437 mRNA and 387 microRNA that showed differential 
expression in at least one treatment group during at least one time point.  
InCroMAP is an enrichment analysis tool with the ability for pathway-based 
visualization of multi omics data. The differentially expressed mRNAs, 
microRNAs, and proteins from the 450 nM treatment group were used as input 
and KEGG pathways that showed over-representation at all time points were 
subjected for integrated visualization of the multi omics expression values. The 
visualization revealed several interesting expression patterns that show a linkage 
between the proteome, transcriptome, and the regulatory microRNA network. In 
brief, there is a clear effect on the myofibrils (the unit responsible for the 
contractility), on important ion channels, on the mitochondrial associated mRNA 
and proteins, as well as the ribosomal function, especially during the acute toxic 
phase. For many of the areas where mRNAs are affected, doxorubicin also affects 
the associated microRNAs. In summary, the identified differentially expressed 
proteins support results from paper II and III, and the integration of data from 
multiple omics domains strengthens important findings of dysregulated genes and 
microRNAs and identifies potential biomarkers for doxorubicin-induced 
cardiotoxicity. 
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5 DISCUSSION 
In this section, the results presented in this thesis are placed in a general context 
and discussed with regard to related research performed by others and potential 
implications for the reported results. 
5.1 Derivatives from hPSC show stability and 
robustness 
The studies that constitute this thesis demonstrate the potential of using 
specialized cell types derived from hPSC as in vitro models for toxicity studies, also 
for longer time periods. The differentiated hepatocytes used in paper I exhibit a 
stable phenotype that enables a two week study of compound exposure. The 
model shows robustness for the three replicates, both with the measurements of 
viability and also for the more specific induction of steatosis and 
phospholipidosis. Likewise, the hESC-derived cardiomyocytes used in paper II-
IV show a stability in culture throughout the whole two week experiment period 
and the different omics data extracted from the experiments show that the model 
is stable across all replicates. 
5.2 Cellular responses to toxic compound exposure 
Equally important as the displayed stability and robustness, of the two 
investigated hPSC-derived cell types, are the cells’ adequate responses to the toxic 
compound exposure. In paper I, the hepatocytes show sensitivity towards the 
known hepatotoxic compounds amiodarone, aflatoxin, and troglitazone, a 
sensitivity that is increased with prolonged exposure. These results reflect the 
functionality of the cells as the high sensitivity to amiodarone and aflatoxin 
correlates to the high CYP3A activity seen in these cells, since both compounds 
are dependent on CYP3A activity to give toxic metabolites109, 110. The hiPS-HEP 
also show sensitivity to troglitazone, at least at higher concentrations, although 
the dose-response curve is more ambiguous as compared to the results on 
amiodarone and aflatoxin. This might be a reflection of the hypothesis that 
troglitazone is toxic both in its original form and as a metabolite111, and that the 
idiosyncratic toxicity associated with troglitazone involves bile salt accumulation 
and bile acid toxicity112. In addition to these findings, a time-dependent increase 
in amiodarone-induced phospholipidosis and troglitazone-induced steatosis is 
observed, suggesting a hepatocyte-specific toxic response.  
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The cardiomyocytes used in paper II-IV are able to recapitulate many of the 
cellular events taking place in cardiomyocytes during doxorubicin-induced 
toxicity. The cells display a clear acute toxic response to doxorubicin, detected by 
a dose-dependent increase in the release of the general cytotoxicity marker LDH 
and the specific cardiotoxicity marker cTnT, in addition to a clear effect of 
doxorubicin on the cells morphological appearance and contractility. Global 
analysis of the transcriptomics data identifies several clusters of genes that show 
differential expression between the treatment groups. ORA of the dysregulated 
genes showed a clear association to cellular defense mechanisms and the p53-
signaling pathway. Genes like Cycline dependent kinase inhibitor 1A (CDKN1A), 
GADD45A, Ribonucleotide Reductase Regulatory TP53 Inducible Subunit M2B  
(RRM2B), Ring Finger Protein 144B (RNF144B), and MDM2 Proto-Oncogene 
(MDM2) have been reported to play important roles during DNA damage and 
repair and p53 induced apoptosis and cell cycle arrest113-117. Among the altered 
genes, we also detected genes related to cytoskeleton remodeling, such as Plexin 
A2 (PLXNA2) and Dihydropyrimidinase Like 4 (DPYSL4)118, 119, and the cardiac 
specific genes Potassium Voltage-Gated Channel Subfamily J Member 2 (KCNJ2) 
and Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 2 
(HCN2), encoding for two important potassium channels120, 121. Further, we 
report in paper III the effects of doxorubicin on the cardiomyocytes’ microRNA 
expression. Sets of microRNAs that were significantly dysregulated by 
doxorubicin were identified, some of which are affected throughout the entire 
experiment. Several of the identified microRNAs might have roles in mechanisms 
underlying the cardiotoxicity. The microRNA miR-146a, is suggested to, via the 
Fos/Activator protein 1 (Fos/AP-1) pathway, have an inhibitory effect on matrix 
metalloproteinases122, 123, whose expression show a correlation to heart failure124. 
The complex of miR-199a, miR-199b, and miR-214, is downregulated in dilated 
cardiomyopathy125 and this has been reported to result in morphological changes 
in cardiomyocytes126-128. In addition, miR-424 downregulation might cause 
increased cell death due to reduced inhibition of the tumor suppressor 
Programmed Cell Death 4 (PDCD4)129. Over-representation analysis of the 
identified microRNAs supports the idea that these microRNAs are involved in, 
for this study, relevant biological processes, such as Toll/Toll-like receptor 
signaling; ErbB signaling; apoptosis; and inflammatory responses. The putative 
effects of the identified microRNAs correlate well with the different functions, 
such as DNA damage response; cardiomyocyte survival; inflammation; and 
energetic stress, which currently attracts much interest as key players for 
explaining anthracycline-induced cardiotoxicity51. The study in paper IV, with the 
proteomic analysis of the cardiomyocytes, provides one additional level of 
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complexity to previous studies. The result from the protein analysis showed a 
clear effect of doxorubicin in the cells, with a dose-dependent increase of the 
number of differentially expressed proteins in all four time points. Groups of 
differentially expressed proteins with different expression profiles and involved 
in different biological processes were identified. There is an early triggering of 
apoptotic signaling with upregulation of e.g. TP53I3 and BCL2 Associated 
Athanogene 3 (BAG3). An early downregulation of AMP-activated protein 
kinases (AMPKs) which are involved in p53-dependent DNA damage response 
and apoptosis130 was also detected. AMPKs does have a key role in energy and 
nutrient signaling and the subsequent shift towards upregulation of these proteins 
correlates with reports of a metabolic shift in cardiomyocytes during heart 
failure131, 132. A large portion of the cluster of differentially expressed proteins that 
show an upregulation over time is associated with oxidative phosphorylation, fatty 
acid metabolism, and Krebs cycle. Doxorubicin also affects proteins related to 
the regulation of the free iron within the cell, something that has been reported 
to cause cellular damage133. In general, doxorubicin seems to cause effects on key 
proteins related to the cardiomyocyte function and energy production, which 
correlates well with the events taking place on the transcriptional level. 
5.3 Comparison to other models for toxicity study 
The results in paper I show a similar compound sensitivity for hiPS-HEP as for 
the widely used HepG2 model during the acute exposure. But since HepG2 is 
impracticable for long term exposure due to extensive proliferation, this 
emphasizes the advantage of the hiPS-HEP model for long term studies. The 
hiPS-HEP demonstrated a similar ranking of the sensitivity to the tested 
compounds as for PHH78, 134, 135. At the same time, the general lack of long-term 
toxicity studies using PHH illustrates the challenges of maintaining these cells in 
traditional 2D culture for extended time periods. A recent study assessed four 
different 2D cultured hepatic cell models (including HEPG2, PHH, Upcyte 
hepatocytes, and HepaRG) for their ability to detect DILI-compounds25. This 
study revealed that PHH were the most sensitive cell type, identifying eight out 
of nine hepatotoxic test compounds, followed by HepG2 cells (6/9), whereas 
HepaRG cells were relatively insensitive (3/9), but none of the cell models could 
fully distinguish between DILI and non-DILI compounds. The authors 
concluded that basic cell health endpoints will not predict hepatotoxic risk in 
simple hepatic cells in the absence of pharmacokinetic data and that more 
sophisticated signals of molecular initiating events is required to potentially 
include these cell model in early safety assessment in the pharmaceutical industry. 
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The study emphasizes the need for more predictive in vitro models and much focus 
is directed towards various 3D culture strategies in an attempt to preserve liver 
properties in vitro. The development of 3D liver models has so far been rewarding 
and systems are available whose sensitivity and specificity in detecting 
hepatotoxicity are superior to those of classical 2D culture systems136. The hiPS-
HEP model assessed in paper I will most likely also benefit from 3D culture 
conditions to improve functionality and sensitivity to hepatotoxic compounds. 
The 3D cultures, together with the development of co-culture model systems, are 
most likely essential for future detection of problematic DILI compounds such 
as Ximelagatran, studied in paper I. Ximelagatran, a direct thrombin inhibitor, 
was withdrawn from the market due to elevated levels of alanine aminotransferase 
in patients. Short term use of Ximelagatran has not indicated a hepatotoxic 
potential in clinical trials, and increased rates of elevated liver enzymes was first 
observed after long-term (>35 days) use of ximelagatran. Investigations with 
PHH did not result in a decrease in cell viability, not even with concentrations of 
ximelagatran considerably higher than peak plasma concentrations137. Standard 
preclinical toxicological studies showed no indications of the hepatotoxic effect 
of ximelagatran, nor has any human-based in vitro model been able to define 
mechanisms observed in the long-term clinical trials138. In line with other existing 
human-based in vitro models for hepatotoxicity, the hiPS-HEP model did not 
detect a toxic response to Ximelagatran. The lack of predictive findings for the 
toxicity of ximelagatran is probably a reflection of the need for long-term 
exposure to the compound as well as the probable involvement of class II human 
leukocyte antigens139. 
When turning to cardiomyocyte models to study anthracycline-induced 
cardiotoxicity, the traditional cardiac models suffer from the common 
shortcomings of available models, i.e. species differences for the animal models 
and limited focus for the commonly used cell lines with artificially over expressed 
single ion channels. Therefore, during recent years, much interest has been 
focused on the use of hPSC-derived cardiomyocytes to study anthracycline-
induced cardiotoxicity. Two recently published papers report similar studies as 
the ones conducted in this thesis140, 141, both showing a considerable overlap of 
the findings of differentially expressed mRNAs and microRNAs reported here. 
The high correlation between the studies using a similar cell model, together with 
the high similarity to the responses seen in the human heart in vivo, strengthen the 
hPSC-derived cardiomyocytes as a relevant in vitro model for this type of toxicity 
studies. Furthermore, one additional research group studying doxorubicin-
induced cardiotoxicity in hPSC-derived cardiomyocytes highlights a key feature 
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with hPSC-derived cell models. In a recent paper, they demonstrate that patient-
specific hiPSC-derived cardiomyocytes can recapitulate the susceptibility to 
doxorubicin-induced cardiotoxicity of individual patients at the cellular level142. 
They show that hPSC-derived cardiomyocytes from patients who experienced 
doxorubicin-induced cardiotoxicity were consistently more sensitive to 
doxorubicin toxicity in vitro compared to cardiomyocytes derived from patients 
who did not experience doxorubicin-induced cardiotoxicity. Taken together, 
these studies indicate that hPSC-derived cardiomyocytes are suitable as a platform 
for the study and characterization of the molecular mechanisms of doxorubicin-
induced cardiotoxicity.    
5.4 Mechanistic studies of the doxorubicin-induced 
cardiotoxicity 
One major advantage of using cell culture for toxicological investigations, which 
is highlighted in this thesis, is the suitability for detailed mechanistic studies. Cells 
derived from hPSC can in combination with omics analysis constitute the 
formation of complex in vitro models for mechanistic studies of e.g. drug-induced 
toxicity. Papers II-IV in this thesis confirm that hPSC constitute a relevant 
platform for mechanistic studies of drug-induced toxicity. The studies identify 
mRNAs, proteins, and microRNAs that are dysregulated by doxorubicin and the 
integration of the three omics datasets strengthen the findings from the three 
individual studies on the effects of doxorubicin. It seems that many of the key 
processes affected by doxorubicin exposure are identified on all three biological 
levels. There are several examples of markers that show a correlated dysregulation 
on both mRNA and protein level, linked to a negative correlation to associated 
microRNA. 
For the mechanistic investigation of responses to toxic stimuli, one should bear 
in mind that differential expression of specific genes not per se results in 
activation of a toxicity pathway. There are numerous stress response pathways 
that have evolved to allow cells and tissues to handle and cope with different 
kinds of stress and maintain or restore homeostasis. Perhaps the most well-known 
stress response pathway is the p53 signaling pathway that is initiated in cells with 
damaged DNA, activating gene transcription that, depending on the context, can 
lead to apoptosis in order to protect the tissue. Stress response pathways are not 
the cause of the disturbed biological process but rather the response to the 
disturbed biological process. For the mechanistic study of toxicity one therefore 
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often also refer to toxicity pathways and adverse outcome pathways as the events 
causing dysfunction of a cell, tissue, or organ where whole body homeostasis no 
longer can be maintained143. Having that said, stress response pathways will still 
be of high relevance in the field of toxicology and further identification and 
interpretation of these pathways is critical for deeper mechanistic understanding 
of cells’ responses to toxic stimuli. 
5.5 Potential biomarkers of doxorubicin-induced 
cardiotoxicity 
Thorough mechanistic studies are important for detailing biological events, but 
for in vitro models to be successfully implemented in regular safety assessment 
during drug development screening, scalable and inexpensive model systems are 
needed. Consequently, biomarker discovery and validation is a very important 
task. In that perspective, the studies conducted in paper II-IV were designed to 
interrogate the hPSC-derived cardiomyocytes’ utility to identify potential (novel) 
biomarkers for doxorubicin-induced cardiotoxicity.  
One interesting finding in the study reported in paper II was the dysregulation of 
the gene GDF15 during doxorubicin exposure. Many studies in recent years have 
associated GDF15 with heart disease and suggests GDF15 as a potential 
biomarker for cardiovascular events144-148. However, to our knowledge only one 
study has reported an association between GDF15 and anthracycline-induced 
cardiotoxicity149. GDF15 is activated by e.g. Tumor protein P53 (TP53) and 
Tumor necrosis factor (TNF) and resides in the periphery of the p53-signaling 
network. The protein-protein interaction network reported in paper II show a 
link between GDF15 and proteins like Hepcidin Antimicrobial Peptide (HAMP) 
and Hypoxia Inducible Factor 1 Alpha Subunit (HIF1A). HAMP has a role in 
iron homeostasis150, 151 with a probable importance for doxorubicin-induced 
cardiotoxicity, while HIF1A is thought to be involved in dexarazoxane-mediated 
protection against doxorubicin-induced toxicity152. In addition, we identified 
several other genes with expression profiles similar to GDF15, possibly co-
regulated or involved in similar processes, and these are interesting for further 
investigations. In paper III we also identified three microRNAs, miR-34a; miR-
34b; and miR-187, which showed a dose-dependent upregulation upon 
doxorubicin exposure, an upregulation that was sustained throughout the whole 
experiment and therefore makes them very interesting as potential biomarkers. 
Of these, the miR-34 family are the microRNAs that historically has generated 
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most interest due to the association with cardiac function and disease. Several 
reports suggest that miR-34a has a key role in cardiac injury and repair153, and it 
has been shown in mice that miR-34a is upregulated upon doxorubicin prior to 
the detection of elevated plasma levels of cardiac troponin154. MicroRNA miR-
34b has been associated with myo-pathological disease155, while miR-187 mostly 
has been mentioned as a cancer biomarker but it has also been reported to have 
an effect on inflammatory pathways156. In our data, all three microRNAs exhibit 
very attracting expression profiles as potential biomarkers for the doxorubicin-
induced toxicity. They show an early response to the exposure, especially miR-
34a and miR-34b, and a clear dose-response to doxorubicin that is sustained 
throughout the wash-out period.  
The future of in vitro toxicology will most likely rely on sets of biomarkers that 
gives information about which pathways that are active due to the compound 
exposure. These molecular initiating events conducts the basis of the pathways 
resulting in adverse outcome. Identification of which pathways are activated by a 
specific compound tells us about the biological process which has been interfered. 
5.6 Advantages of hPSC-based in vitro models 
The use of cells derived from hPSC as in vitro models for toxicity studies offers 
several advantages, many of which have been addressed in this thesis. The most 
apparent advantages are the unlimited cell supply due to the self-renewal capacity 
of hPSC, together with their differentiation ability into virtually any cell type. The 
latter offers the possibility to study fully functional cells as well as cells at different 
developmental or maturation stages. The cells can be derived from a stable genetic 
background and with the possibility to generate cells from individuals of a desired 
genetic background. The cells can be up scaled to enable high-throughput 
screening and analysis, a feature that is very appealing for regular safety 
assessment in the pharmaceutical industry.  
One disadvantage of in vitro models in comparison to whole animal studies are 
their lack of the complete organism perspective, the in vivo perspective. However, 
this can to some extent be addressed by hPSC with their potential to generate 
complex in vitro models of multiple cell types and tissue-like cultures. They also 
possess the possibility for sophisticated co-culturing with e.g. immune cells, to 
mimic immunological influences of toxic events. Furthermore, as this thesis 
demonstrate, an hPSC-based in vitro model is highly suitable for mechanistic 
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studies on several biological levels, especially if combined with advanced omics 
technologies.   
5.7 Limitations of this work 
The apparent successful use of hPSC-derived hepatocytes for toxicity assessment 
is somewhat limited by the fact that these cells are not functionally equivalent to 
PHH. Cultures are not completely homogenous and typically display population 
of cells exhibiting immature and mature markers simultaneously. However, there 
are recent reports on the clear improvements of the differentiation procedures of 
hPSC-derived hepatocytes, both in the dynamic use of the same protocol for 
several stem cell lines, as well as the fact that the hepatic phenotypes of the 
differentiated cells tangent to functional levels of PHH71, 157.  
The same applies to the cardiomyocytes as these cultures possess a population of 
cardiomyocytes with mixed phenotypes, expressing both immature and mature 
markers and ventricular-, atrial, and nodal phenotypes (reviewed by Barbuti A. et 
al.158).   
Regarding the statement by Paracelsus that “the dose makes the poison”, a 
limitation in the type of chemical safety assessment studies performed here, is that 
the applied concentration most likely is not the ‘free’ concentration of the 
compounds in the cell cultures, and therefore might not be representative for the 
plasma concentrations in vivo. Despite this, for decades researchers have 
performed toxicity experiments, both in cell culture and in animals, with 
compound concentrations of lethal dose 50% (LD50), often resulting in 
unreasonably high concentrations, especially for less harmful compounds. We 
have in some aspects tried to address this issue during the conducted studies, by 
exposing the cells to concentration well below LD50, aiming for a concentration 
range around lethal dose 10% (LD10). However, in these studies we have not 
investigated the pharmacokinetics or biokinetics of the compounds and therefore 
cannot be certain that the applied concentrations are the effective concentrations, 
and if they are clinically or biologically relevant or not. 
For some of the key genes affected by doxorubicin-induced toxicity where we 
demonstrate a clear effect on the mRNA level, there is no differential expression 
detected on the protein level. For example, the main targets for doxorubicin, 
Topoisomerase (DNA) II alpha (TOP2A) and Topoisomerase (DNA) II beta 
(TOP2B) show a clear effect on the mRNA expression but no significant 
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differential expression on the protein level. This discrepancy highlights one 
possible limitation of this study, since the measurement of protein abundance 
might not reflect the dysfunctional proteins caused by doxorubicin. Much of the 
effects of doxorubicin involves activation or inactivation of proteins, 
phosphorylation, disruption of protein complexes, and in other ways inhibition 
of protein functions, effects that are not detected when simply analyzing the 
abundance of the proteins. Another possible limitation in the proteomic 
technique used for this study is the ‘bottom up’ approach to identify and measure 
the abundance of proteins. The approach uses the peptides for identification and 
quantification and there is a risk that not all comes from a single protein species, 
the same peptide might originate from several protein isoforms. This might lead 
to a risk of incorrect conclusions if the results are interpreted as the behavior of 
a single polypeptide in the cell, when in fact it can be the average of several 
polypeptides with different characteristics. However, measures are taken against 
this problem during the analysis of the raw data and only peptides that are unique 
to a given protein are considered for relative quantification, which in turn 
substantially reduces the number of proteins identified and quantified. In 
addition, the method is ‘data-dependent’, meaning that it randomly samples the 
population of peptides that is injected into the mass spectrometer, which 
influences the range of peptides identified and quantified. These limitations might 
be reflected in the case with the identified potential biomarker GDF15 reported 
in paper II, which in the mRNA data show high expression level and a clear 
differential expression upon doxorubicin exposure but despite that, it is not 
detected in any sample at the protein level. 
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6 CONCLUSIONS AND FUTURE 
PERSPECTIVE 
This thesis shows the potential of using hPSC derivatives as in vitro models for 
toxicity studies. The results demonstrate the diverse applicability of hPSC as a 
source for representative cells, and they also illustrate how robust and 
reproducible the differentiation of hPSC has become. The thesis also display the 
cells’ relevant responses to toxic stimuli and their ability for deep mechanistic 
exploration of the toxic response.  
The studies in this thesis are well in line with the strategy of the three R’s (reduce, 
refine, and replace) in the use of animal models. In vitro models based on cells 
from hPSC offer a promising alternative to animal models, with the potential of 
being more predictive for the human in vivo situation. In conjunction with omics 
technologies, that provide a system view of cellular events, the development of 
new mechanistic biomarker sets will be easier achieved. The thesis demonstrates 
that the integration of several omics branches can provide a deeper understanding 
of the mechanisms on how compounds disturb normal biological processes and 
functions. The thesis lends additional support to that all necessary tools for the 
implementation of the vision of the new toxicity strategy are available. The studies 
performed follow this new strategy by using hPSC derivatives together with 
integration of omics data from multiple levels, to investigate the mechanisms 
behind the specific doxorubicin-induced toxicity, identify toxicity pathways and 
potential biomarkers, and ultimately result in the development of a test model for 
this type of toxicity. 
The in vitro models insufficiency of the in vivo resemblance is an impediment for 
the use of in vitro models for toxicity predictions. In that perspective, a future 
technology that seems promising is the organoid-on-a-chip, advanced culture 
devices that can recapitulate the 3D tissue structure and physiological conditions 
of normal tissues. In general, 3D systems exceed 2D cultures in regard to in vivo 
resemblance and the response to drugs and toxins159. The advances in tissue 
engineering, biomaterials, and microfluidic technologies enable the assembly of 
organoid-on-a-chip devices, multicellular 3D cultures approaching in vivo 
physiology. 3D organoids constructed of e.g. liver or cardiac cells show 
advantages in functionality compared to traditional cultures and maintain viability 
for 4 weeks or beyond160. These organoid-on-a-chip technologies might also offer 
the possibility to construct even more advanced multi-organ systems, so called 
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body-on-a-chip, which for example opens up for the appealing idea of allowing 
metabolism of a prodrug (or compound) in a liver organoid prior to the 
assessment of the active drug (or toxicant) in downstream tissues or target 
organoids160.   
As pointed out by Paul Jennings in 2015161, there are two major issues that 
researchers and toxicologists in the future will have to address. First, the variety 
of choices when setting up an in vitro system is huge. The decisions of which cells 
to use, 2D vs 3D, static medium changes vs medium perfusion, etc. are not easy 
and will not be easier as we create more complex and sophisticated cell culture 
system. Secondly, how can we capture the large genetic and epigenetic diversity 
there is? A cell or cell type derived from one individual cannot recapitulate the 
population variability. The first issue is to some extent addressed in the different 
major international consortia such as the CiPA-initiative or the “Safety Evaluation 
Ultimately Replacing Animal Testing” (SEURAT-1), which aim towards 
evaluating available safety assessment models, and to develop and standardize 
innovative testing methods for future safety assessment. Studies, such as the ones 
conducted in this thesis, also aid in evaluating the field of new innovative in vitro 
models. Human iPSC have the potential of addressing the second issue, since they 
allow the possibility to generate target cells/tissues from any individual. However, 
increasing the complexity of an in vitro system, by for instance including a panel 
of cells derived from diverse genetic background, will unavoidably decrease the 
throughput of the system. 
One appealing idea, supported by the results in this thesis, is that hiPSC, with the 
possibility to represent the population variability, can constitute the basic cell 
source for in vitro compound testing systems. These models can span from simple 
in vitro systems of lowly differentiated monocultures for high throughput toxicity 
screening of compounds, to complex in vitro systems of highly differentiated 
multi-cellular models for lower throughput in-depth mechanistic studies and 
biomarker identification.   
Importantly, in vitro toxicology is a rapidly emerging field of science and it will 
most likely be crucial for future human chemical safety assessment. Using the new 
knowledge of hPSC biology together with omics technology in an integrated 
interdisciplinary manner will enable human in vitro systems to become these 
important toxicological tools, with the potential of replacing animal testing 
completely. 
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